Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
= 33 34 33 34 O
1.0 35 38 35 38 B-lower_bound
x 39 40 39 40 I-lower_bound
10 41 43 41 43 I-lower_bound
^ 43 44 43 44 I-lower_bound
9 44 45 44 45 I-lower_bound
/ 45 46 45 46 I-lower_bound
L 46 47 46 47 I-lower_bound
, 47 48 47 48 O
performed 49 58 49 58 O
within 59 65 59 65 O
28 66 68 66 68 B-upper_bound
days 69 73 69 73 I-upper_bound
of 74 76 74 76 O
treatment 77 86 77 86 B-treatment
initiation 87 97 87 97 O

Aspartate 0 9 98 107 B-clinical_variable
aminotransferase 10 26 108 124 I-clinical_variable
( 27 28 125 126 I-clinical_variable
AST)/serum 28 38 126 136 I-clinical_variable
glutamic 39 47 137 145 I-clinical_variable
oxaloacetic 48 59 146 157 I-clinical_variable
transaminase 60 72 158 170 I-clinical_variable
( 73 74 171 172 I-clinical_variable
SGOT 74 78 172 176 I-clinical_variable
) 78 79 176 177 I-clinical_variable
and 80 83 178 181 O
alanine 84 91 182 189 B-clinical_variable
aminotransferase 92 108 190 206 I-clinical_variable
( 109 110 207 208 I-clinical_variable
ALT)/serum 110 120 208 218 I-clinical_variable
glutamic 121 129 219 227 I-clinical_variable
pyruvic 130 137 228 235 I-clinical_variable
transaminase 138 150 236 248 I-clinical_variable
( 151 152 249 250 I-clinical_variable
SGPT 152 156 250 254 I-clinical_variable
) 156 157 254 255 I-clinical_variable
= 158 159 256 257 O
< 159 160 257 258 O
2.5 161 164 259 262 B-upper_bound
x 165 166 263 264 I-upper_bound
ULN 167 170 265 268 I-upper_bound
OR 171 173 269 271 O
= 174 175 272 273 O
< 175 176 273 274 O
5 177 178 275 276 O
x 179 180 277 278 O
ULN 181 184 279 282 O
for 185 188 283 286 O
subjects 189 197 287 295 O
with 198 202 296 300 O
lymphoma 203 211 301 309 B-cancer
in 212 214 310 312 I-cancer
the 215 218 313 316 I-cancer
liver 219 224 317 322 I-cancer
, 224 225 322 323 O
performed 226 235 324 333 O
within 236 242 334 340 O
28 243 245 341 343 B-upper_bound
days 246 250 344 348 I-upper_bound
of 251 253 349 351 O
treatment 254 263 352 361 B-treatment
initiation 264 274 362 372 O

Female 0 6 373 379 B-gender
subject 7 14 380 387 I-gender
of 15 17 388 390 O
childbearing 18 30 391 403 O
potential 31 40 404 413 O

Female 0 6 414 420 B-gender
subjects 7 15 421 429 I-gender
of 16 18 430 432 O
childbearing 19 31 433 445 O
potential 32 41 446 455 O

Females 0 7 456 463 B-gender
of 8 10 464 466 O
reproductive 11 23 467 479 O
potential 24 33 480 489 O

Has 0 3 490 493 O
a 4 5 494 495 O
diagnosis 6 15 496 505 O
of 16 18 506 508 O
immunodeficiency 19 35 509 525 B-chronic_disease

Has 0 3 526 529 O
a 4 5 530 531 O
history 6 13 532 539 O
or 14 16 540 542 O
current 17 24 543 550 O
evidence 25 33 551 559 O
of 34 36 560 562 O
any 37 40 563 566 O
condition 41 50 567 576 O
, 50 51 576 577 O
therapy 52 59 578 585 B-treatment
, 59 60 585 586 O
or 61 63 587 589 O
laboratory 64 74 590 600 O
abnormality 75 86 601 612 O
that 87 91 613 617 O
might 92 97 618 623 O
confound 98 106 624 632 O
the 107 110 633 636 O
results 111 118 637 644 O
of 119 121 645 647 O
the 122 125 648 651 O
trial 126 131 652 657 O
, 131 132 657 658 O
interfere 133 142 659 668 O
with 143 147 669 673 O
the 148 151 674 677 O
subject 152 159 678 685 O
's 159 161 685 687 O
participation 162 175 688 701 O
for 176 179 702 705 O
the 180 183 706 709 O
full 184 188 710 714 O
duration 189 197 715 723 O
of 198 200 724 726 O
the 201 204 727 730 O
trial 205 210 731 736 O
, 210 211 736 737 O
or 212 214 738 740 O
is 215 217 741 743 O
not 218 221 744 747 O
in 222 224 748 750 O
the 225 228 751 754 O
best 229 233 755 759 O
interest 234 242 760 768 O
of 243 245 769 771 O
the 246 249 772 775 O
subject 250 257 776 783 O
to 258 260 784 786 O
participate 261 272 787 798 O
, 272 273 798 799 O
in 274 276 800 802 O
the 277 280 803 806 O
opinion 281 288 807 814 O
of 289 291 815 817 O
the 292 295 818 821 O
treating 296 304 822 830 O
investigator 305 317 831 843 O

Has 0 3 844 847 O
a 4 5 848 849 O
known 6 11 850 855 O
additional 12 22 856 866 O
malignancy 23 33 867 877 B-cancer
that 34 38 878 882 O
is 39 41 883 885 O
progressing 42 53 886 897 O
and 54 57 898 901 O
requires 58 66 902 910 O
active 67 73 911 917 B-treatment
treatment 74 83 918 927 I-treatment

Has 0 3 928 931 O
a 4 5 932 933 O
known 6 11 934 939 O
history 12 19 940 947 O
of 20 22 948 950 O
human 23 28 951 956 B-chronic_disease
immunodeficiency 29 45 957 973 I-chronic_disease
virus 46 51 974 979 I-chronic_disease
( 52 53 980 981 I-chronic_disease
HIV 53 56 981 984 I-chronic_disease
) 56 57 984 985 I-chronic_disease
( 58 59 986 987 O
HIV 59 62 987 990 O
1/2 63 66 991 994 O
antibodies 67 77 995 1005 O
) 77 78 1005 1006 O

Has 0 3 1007 1010 O
an 4 6 1011 1013 O
active 7 13 1014 1020 B-chronic_disease
infection 14 23 1021 1030 I-chronic_disease
requiring 24 33 1031 1040 O
systemic 34 42 1041 1049 B-treatment
therapy 43 50 1050 1057 I-treatment

Has 0 3 1058 1061 O
evidence 4 12 1062 1070 O
of 13 15 1071 1073 O
interstitial 16 28 1074 1086 B-chronic_disease
lung 29 33 1087 1091 I-chronic_disease
disease 34 41 1092 1099 I-chronic_disease
or 42 44 1100 1102 O
active 45 51 1103 1109 B-chronic_disease
, 51 52 1109 1110 O
non 53 56 1111 1114 B-chronic_disease
- 56 57 1114 1115 I-chronic_disease
infectious 57 67 1115 1125 I-chronic_disease
pneumonitis 68 79 1126 1137 I-chronic_disease
that 80 84 1138 1142 O
required 85 93 1143 1151 O
steroids 94 102 1152 1160 B-treatment
or 103 105 1161 1163 O
current 106 113 1164 1171 B-chronic_disease
pneumonitis 114 125 1172 1183 I-chronic_disease

Has 0 3 1184 1187 O
had 4 7 1188 1191 O
a 8 9 1192 1193 O
prior 10 15 1194 1199 B-treatment
monoclonal 16 26 1200 1210 I-treatment
antibody 27 35 1211 1219 I-treatment
within 36 42 1220 1226 O
4 43 44 1227 1228 B-lower_bound
weeks 45 50 1229 1234 I-lower_bound
prior 51 56 1235 1240 I-upper_bound
to 57 59 1241 1243 O
study 60 65 1244 1249 O
day 66 69 1250 1253 O
1 70 71 1254 1255 O
or 72 74 1256 1258 O
who 75 78 1259 1262 O
has 79 82 1263 1266 O
not 83 86 1267 1270 O
recovered 87 96 1271 1280 O
( 97 98 1281 1282 O
i.e. 98 102 1282 1286 O
, 102 103 1286 1287 O
= 104 105 1288 1289 O
< 105 106 1289 1290 O
grade 107 112 1291 1296 B-upper_bound
1 113 114 1297 1298 I-upper_bound
or 115 117 1299 1301 O
at 118 120 1302 1304 O
baseline 121 129 1305 1313 O
) 129 130 1313 1314 O
from 131 135 1315 1319 O
adverse 136 143 1320 1327 O
events 144 150 1328 1334 O
( 151 152 1335 1336 O
AEs 152 155 1336 1339 O
) 155 156 1339 1340 O
due 157 160 1341 1344 O
to 161 163 1345 1347 O
agents 164 170 1348 1354 O
administered 171 183 1355 1367 O
more 184 188 1368 1372 O
than 189 193 1373 1377 O
4 194 195 1378 1379 O
weeks 196 201 1380 1385 O
earlier 202 209 1386 1393 O

Has 0 3 1394 1397 O
had 4 7 1398 1401 O
prior 8 13 1402 1407 B-treatment
chemotherapy 14 26 1408 1420 I-treatment
, 26 27 1420 1421 O
targeted 28 36 1422 1430 B-treatment
small 37 42 1431 1436 I-treatment
molecule 43 51 1437 1445 I-treatment
therapy 52 59 1446 1453 I-treatment
, 59 60 1453 1454 O
or 61 63 1455 1457 O
radiation 64 73 1458 1467 B-treatment
therapy 74 81 1468 1475 I-treatment
within 82 88 1476 1482 O
2 89 90 1483 1484 B-upper_bound
weeks 91 96 1485 1490 I-upper_bound
prior 97 102 1491 1496 I-upper_bound
to 103 105 1497 1499 O
study 106 111 1500 1505 O
day 112 115 1506 1509 O
1 116 117 1510 1511 O
or 118 120 1512 1514 O
who 121 124 1515 1518 O
has 125 128 1519 1522 O
not 129 132 1523 1526 O
recovered 133 142 1527 1536 O
( 143 144 1537 1538 O
i.e. 144 148 1538 1542 O
, 148 149 1542 1543 O
= 150 151 1544 1545 O
< 151 152 1545 1546 O
grade 153 158 1547 1552 B-upper_bound
1 159 160 1553 1554 I-upper_bound
or 161 163 1555 1557 O
at 164 166 1558 1560 O
baseline 167 175 1561 1569 O
) 175 176 1569 1570 O
from 177 181 1571 1575 O
AEs 182 185 1576 1579 O
due 186 189 1580 1583 O
to 190 192 1584 1586 O
a 193 194 1587 1588 O
previously 195 205 1589 1599 O
administered 206 218 1600 1612 O
agent 219 224 1613 1618 O

Has 0 3 1619 1622 O
known 4 9 1623 1628 O
active 10 16 1629 1635 O
central 17 24 1636 1643 B-cancer
nervous 25 32 1644 1651 I-cancer
system 33 39 1652 1658 I-cancer
( 40 41 1659 1660 I-cancer
CNS 41 44 1660 1663 I-cancer
) 44 45 1663 1664 I-cancer
lymphoma 46 54 1665 1673 I-cancer
and/or 55 61 1674 1680 O
lymphomatous 62 74 1681 1693 B-cancer
meningitis 75 85 1694 1704 I-cancer

Has 0 3 1705 1708 O
known 4 9 1709 1714 O
active 10 16 1715 1721 B-chronic_disease
hepatitis 17 26 1722 1731 I-chronic_disease
B 27 28 1732 1733 I-chronic_disease
( 29 30 1734 1735 O
e.g. 30 34 1735 1739 O
, 34 35 1739 1740 O
hepatitis 36 45 1741 1750 O
B 46 47 1751 1752 O
virus 48 53 1753 1758 O
surface 54 61 1759 1766 O
antigen 62 69 1767 1774 O
[ 70 71 1775 1776 O
HBsAg 71 76 1776 1781 O
] 76 77 1781 1782 O
reactive 78 86 1783 1791 O
) 86 87 1791 1792 O
or 88 90 1793 1795 O
hepatitis 91 100 1796 1805 B-chronic_disease
C 101 102 1806 1807 I-chronic_disease
( 103 104 1808 1809 O
e.g. 104 108 1809 1813 O
, 108 109 1813 1814 O
hepatitis 110 119 1815 1824 B-chronic_disease
C 120 121 1825 1826 I-chronic_disease
virus 122 127 1827 1832 I-chronic_disease
[ 128 129 1833 1834 I-chronic_disease
HCV 129 132 1834 1837 I-chronic_disease
] 132 133 1837 1838 I-chronic_disease
ribonucleic 134 145 1839 1850 B-clinical_variable
acid 146 150 1851 1855 I-clinical_variable
[ 151 152 1856 1857 I-clinical_variable
RNA 152 155 1857 1860 I-clinical_variable
] 155 156 1860 1861 I-clinical_variable
qualitative 157 168 1862 1873 O
is 169 171 1874 1876 O
detected 172 180 1877 1885 O
) 180 181 1885 1886 O

Has 0 3 1887 1890 O
known 4 9 1891 1896 O
psychiatric 10 21 1897 1908 B-chronic_disease
or 22 24 1909 1911 O
substance 25 34 1912 1921 O
abuse 35 40 1922 1927 O
disorders 41 50 1928 1937 O
that 51 55 1938 1942 O
would 56 61 1943 1948 O
interfere 62 71 1949 1958 O
with 72 76 1959 1963 O
cooperation 77 88 1964 1975 O
with 89 93 1976 1980 O
the 94 97 1981 1984 O
requirements 98 110 1985 1997 O
of 111 113 1998 2000 O
the 114 117 2001 2004 O
trial 118 123 2005 2010 O

Has 0 3 2011 2014 O
received 4 12 2015 2023 O
a 13 14 2024 2025 O
live 15 19 2026 2030 B-treatment
vaccine 20 27 2031 2038 I-treatment
within 28 34 2039 2045 O
30 35 37 2046 2048 B-upper_bound
days 38 42 2049 2053 I-upper_bound
prior 43 48 2054 2059 I-upper_bound
to 49 51 2060 2062 O
the 52 55 2063 2066 O
first 56 61 2067 2072 O
dose 62 66 2073 2077 O
of 67 69 2078 2080 O
trial 70 75 2081 2086 O
treatment 76 85 2087 2096 B-treatment

Has 0 3 2097 2100 O
received 4 12 2101 2109 O
prior 13 18 2110 2115 B-treatment
therapy 19 26 2116 2123 I-treatment
with 27 31 2124 2128 I-treatment
an 32 34 2129 2131 I-treatment
anti 35 39 2132 2136 I-treatment
- 39 40 2136 2137 I-treatment
programmed 40 50 2137 2147 I-treatment
cell 51 55 2148 2152 I-treatment
death 56 61 2153 2158 I-treatment
1 62 63 2159 2160 I-treatment
( 64 65 2161 2162 I-treatment
PD-1 65 69 2162 2166 I-treatment
) 69 70 2166 2167 I-treatment
, 70 71 2167 2168 I-treatment
anti 72 76 2169 2173 I-treatment
- 76 77 2173 2174 I-treatment
programmed 77 87 2174 2184 I-treatment
cell 88 92 2185 2189 I-treatment
death 93 98 2190 2195 I-treatment
ligand 99 105 2196 2202 I-treatment
1 106 107 2203 2204 I-treatment
( 108 109 2205 2206 I-treatment
PD 109 111 2206 2208 I-treatment
- 111 112 2208 2209 I-treatment
L1 112 114 2209 2211 I-treatment
) 114 115 2211 2212 I-treatment
, 115 116 2212 2213 I-treatment
anti 117 121 2214 2218 I-treatment
- 121 122 2218 2219 I-treatment
programmed 122 132 2219 2229 I-treatment
cell 133 137 2230 2234 I-treatment
death 138 143 2235 2240 I-treatment
ligand 144 150 2241 2247 I-treatment
2 151 152 2248 2249 I-treatment
( 153 154 2250 2251 I-treatment
PD 154 156 2251 2253 I-treatment
- 156 157 2253 2254 I-treatment
L2 157 159 2254 2256 I-treatment
) 159 160 2256 2257 I-treatment
, 160 161 2257 2258 I-treatment
anti- 162 167 2259 2264 I-treatment
cluster 168 175 2265 2272 I-treatment
of 176 178 2273 2275 I-treatment
differentiation 179 194 2276 2291 I-treatment
( 195 196 2292 2293 I-treatment
CD)137 196 202 2293 2299 I-treatment
, 202 203 2299 2300 I-treatment
or 204 206 2301 2303 I-treatment
anti 207 211 2304 2308 I-treatment
- 211 212 2308 2309 I-treatment
cytotoxic 212 221 2309 2318 I-treatment
T 222 223 2319 2320 I-treatment
- 223 224 2320 2321 I-treatment
lymphocyte 224 234 2321 2331 I-treatment
- 234 235 2331 2332 I-treatment
associated 235 245 2332 2342 I-treatment
antigen-4 246 255 2343 2352 I-treatment
( 256 257 2353 2354 I-treatment
CTLA-4 257 263 2354 2360 I-treatment
) 263 264 2360 2361 I-treatment
antibody 265 273 2362 2370 I-treatment
( 274 275 2371 2372 O
including 275 284 2372 2381 O
ipilimumab 285 295 2382 2392 B-treatment
or 296 298 2393 2395 O
any 299 302 2396 2399 O
other 303 308 2400 2405 O
antibody 309 317 2406 2414 O
or 318 320 2415 2417 O
drug 321 325 2418 2422 B-treatment
specifically 326 338 2423 2435 O
targeting 339 348 2436 2445 O
T 349 350 2446 2447 O
- 350 351 2447 2448 O
cell 351 355 2448 2452 O
co 356 358 2453 2455 O
- 358 359 2455 2456 O
stimulation 359 370 2456 2467 O
or 371 373 2468 2470 O
checkpoint 374 384 2471 2481 O
pathways 385 393 2482 2490 O
) 393 394 2490 2491 O

Have 0 4 2492 2496 O
a 5 6 2497 2498 O
performance 7 18 2499 2510 B-clinical_variable
status 19 25 2511 2517 I-clinical_variable
of 26 28 2518 2520 O
0 29 30 2521 2522 B-lower_bound
or 31 33 2523 2525 O
1 34 35 2526 2527 B-upper_bound
on 36 38 2528 2530 O
the 39 42 2531 2534 O
Eastern 43 50 2535 2542 B-clinical_variable
Cooperative 51 62 2543 2554 I-clinical_variable
Oncology 63 71 2555 2563 I-clinical_variable
Group 72 77 2564 2569 I-clinical_variable
( 78 79 2570 2571 I-clinical_variable
ECOG 79 83 2571 2575 I-clinical_variable
) 83 84 2575 2576 I-clinical_variable
performance 85 96 2577 2588 I-clinical_variable
scale 97 102 2589 2594 I-clinical_variable

Have 0 4 2595 2599 O
measurable 5 15 2600 2610 O
disease 16 23 2611 2618 O
( 24 25 2619 2620 O
> 25 26 2620 2621 O
= 26 27 2621 2622 O
1.5 28 31 2623 2626 B-lower_bound
cm 32 34 2627 2629 I-lower_bound
in 35 37 2630 2632 O
the 38 41 2633 2636 O
longest 42 49 2637 2644 O
diameter 50 58 2645 2653 O
for 59 62 2654 2657 O
nodal 63 68 2658 2663 B-chronic_disease
or 69 71 2664 2666 I-chronic_disease
extranodal 72 82 2667 2677 I-chronic_disease
disease 83 90 2678 2685 I-chronic_disease
) 90 91 2685 2686 O

Hemoglobin 0 10 2687 2697 B-clinical_variable
> 11 12 2698 2699 O
= 12 13 2699 2700 O
8.0 14 17 2701 2704 B-lower_bound
g 18 19 2705 2706 I-lower_bound
/ 19 20 2706 2707 I-lower_bound
dL 20 22 2707 2709 I-lower_bound
, 22 23 2709 2710 O
performed 24 33 2711 2720 O
within 34 40 2721 2727 O
28 41 43 2728 2730 B-upper_bound
days 44 48 2731 2735 I-upper_bound
of 49 51 2736 2738 O
treatment 52 61 2739 2748 B-treatment
initiation 62 72 2749 2759 O

International 0 13 2760 2773 B-clinical_variable
normalized 14 24 2774 2784 I-clinical_variable
ratio 25 30 2785 2790 I-clinical_variable
( 31 32 2791 2792 I-clinical_variable
INR 32 35 2792 2795 I-clinical_variable
) 35 36 2795 2796 I-clinical_variable
or 37 39 2797 2799 O
prothrombin 40 51 2800 2811 B-clinical_variable
time 52 56 2812 2816 I-clinical_variable
( 57 58 2817 2818 I-clinical_variable
PT 58 60 2818 2820 I-clinical_variable
) 60 61 2820 2821 I-clinical_variable
= 62 63 2822 2823 O
< 63 64 2823 2824 O
1.5 65 68 2825 2828 B-upper_bound
x 69 70 2829 2830 I-upper_bound
ULN 71 74 2831 2834 I-upper_bound
unless 75 81 2835 2841 O
subject 82 89 2842 2849 O
is 90 92 2850 2852 O
receiving 93 102 2853 2862 O
anticoagulant 103 116 2863 2876 B-treatment
therapy 117 124 2877 2884 I-treatment
as 125 127 2885 2887 O
long 128 132 2888 2892 O
as 133 135 2893 2895 O
PT 136 138 2896 2898 O
or 139 141 2899 2901 O
partial 142 149 2902 2909 B-clinical_variable
thromboplastin 150 164 2910 2924 I-clinical_variable
time 165 169 2925 2929 I-clinical_variable
( 170 171 2930 2931 I-clinical_variable
PTT 171 174 2931 2934 I-clinical_variable
) 174 175 2934 2935 I-clinical_variable
is 176 178 2936 2938 O
within 179 185 2939 2945 O
therapeutic 186 197 2946 2957 O
range 198 203 2958 2963 O
of 204 206 2964 2966 O
intended 207 215 2967 2975 O
use 216 219 2976 2979 O
of 220 222 2980 2982 O
anticoagulants 223 237 2983 2997 B-treatment

Male 0 4 2998 3002 B-gender

Male 0 4 3003 3007 B-gender
subjects 5 13 3008 3016 I-gender

No 0 2 3017 3019 O
active 3 9 3020 3026 O
autoimmune 10 20 3027 3037 B-chronic_disease
disease 21 28 3038 3045 I-chronic_disease
that 29 33 3046 3050 O
has 34 37 3051 3054 O
required 38 46 3055 3063 O
systemic 47 55 3064 3072 B-treatment
treatment 56 65 3073 3082 I-treatment
in 66 68 3083 3085 O
past 69 73 3086 3090 B-upper_bound
2 74 75 3091 3092 I-upper_bound
years 76 81 3093 3098 I-upper_bound
( 82 83 3099 3100 O
i.e. 83 87 3100 3104 O
with 88 92 3105 3109 O
use 93 96 3110 3113 O
of 97 99 3114 3116 O
disease 100 107 3117 3124 O
modifying 108 117 3125 3134 O
agents 118 124 3135 3141 O
, 124 125 3141 3142 O
corticosteroids 126 141 3143 3158 B-treatment
or 142 144 3159 3161 O
immunosuppressive 145 162 3162 3179 B-treatment
drugs 163 168 3180 3185 I-treatment
) 168 169 3185 3186 O

Platelets 0 9 3187 3196 B-clinical_variable
> 10 11 3197 3198 O
= 11 12 3198 3199 O
75 13 15 3200 3202 B-lower_bound
x 16 17 3203 3204 I-lower_bound
10 18 20 3205 3207 I-lower_bound
^ 20 21 3207 3208 I-lower_bound
9 21 22 3208 3209 I-lower_bound
/ 22 23 3209 3210 I-lower_bound
L 23 24 3210 3211 I-lower_bound
, 24 25 3211 3212 O
performed 26 35 3213 3222 O
within 36 42 3223 3229 O
28 43 45 3230 3232 B-upper_bound
days 46 50 3233 3237 I-upper_bound
of 51 53 3238 3240 O
treatment 54 63 3241 3250 B-treatment
initiation 64 74 3251 3261 O

Serum 0 5 3262 3267 B-clinical_variable
creatinine 6 16 3268 3278 I-clinical_variable
OR 17 19 3279 3281 O
measured 20 28 3282 3290 O
or 29 31 3291 3293 O
calculated 32 42 3294 3304 B-clinical_variable
creatinine 43 53 3305 3315 I-clinical_variable
clearance 54 63 3316 3325 I-clinical_variable
( 64 65 3326 3327 O
glomerular 65 75 3327 3337 B-clinical_variable
filtration 76 86 3338 3348 I-clinical_variable
rate 87 91 3349 3353 I-clinical_variable
[ 92 93 3354 3355 I-clinical_variable
GFR 93 96 3355 3358 I-clinical_variable
] 96 97 3358 3359 I-clinical_variable
can 98 101 3360 3363 O
also 102 106 3364 3368 O
be 107 109 3369 3371 O
used 110 114 3372 3376 O
in 115 117 3377 3379 O
place 118 123 3380 3385 O
of 124 126 3386 3388 O
creatinine 127 137 3389 3399 O
or 138 140 3400 3402 O
creatinine 141 151 3403 3413 B-clinical_variable
clearance 152 161 3414 3423 I-clinical_variable
[ 162 163 3424 3425 I-clinical_variable
CrCl 163 167 3425 3429 I-clinical_variable
] 167 168 3429 3430 I-clinical_variable
) 168 169 3430 3431 I-clinical_variable
( 170 171 3432 3433 O
creatinine 171 181 3433 3443 O
clearance 182 191 3444 3453 O
will 192 196 3454 3458 O
be 197 199 3459 3461 O
calculated 200 210 3462 3472 O
per 211 214 3473 3476 O
institutional 215 228 3477 3490 O
standard 229 237 3491 3499 O
) 237 238 3499 3500 O
= 239 240 3501 3502 O
< 240 241 3502 3503 O
1.5 242 245 3504 3507 B-upper_bound
x 246 247 3508 3509 I-upper_bound
upper 248 253 3510 3515 I-upper_bound
limit 254 259 3516 3521 I-upper_bound
of 260 262 3522 3524 I-upper_bound
normal 263 269 3525 3531 I-upper_bound
( 270 271 3532 3533 I-upper_bound
ULN 271 274 3533 3536 I-upper_bound
) 274 275 3536 3537 I-upper_bound
OR 276 278 3538 3540 O
> 279 280 3541 3542 O
= 280 281 3542 3543 O
60 282 284 3544 3546 B-lower_bound
mL 285 287 3547 3549 I-lower_bound
/ 287 288 3549 3550 I-lower_bound
min 288 291 3550 3553 I-lower_bound
GFR 292 295 3554 3557 O
or 296 298 3558 3560 O
CrCl 299 303 3561 3565 O
for 304 307 3566 3569 O
subjects 308 316 3570 3578 O
with 317 321 3579 3583 O
creatinine 322 332 3584 3594 B-clinical_variable
levels 333 339 3595 3601 I-clinical_variable
> 340 341 3602 3603 O
1.5 342 345 3604 3607 B-lower_bound
x 346 347 3608 3609 I-lower_bound
institutional 348 361 3610 3623 I-lower_bound
ULN 362 365 3624 3627 I-lower_bound
, 365 366 3627 3628 O
performed 367 376 3629 3638 O
within 377 383 3639 3645 O
28 384 386 3646 3648 B-upper_bound
days 387 391 3649 3653 I-upper_bound
of 392 394 3654 3656 O
treatment 395 404 3657 3666 B-treatment
initiation 405 415 3667 3677 O

Serum 0 5 3678 3683 B-clinical_variable
total 6 11 3684 3689 I-clinical_variable
bilirubin 12 21 3690 3699 I-clinical_variable
= 22 23 3700 3701 O
< 23 24 3701 3702 O
1.5 25 28 3703 3706 B-upper_bound
x 29 30 3707 3708 I-upper_bound
ULN 31 34 3709 3712 I-upper_bound
OR 35 37 3713 3715 O
direct 38 44 3716 3722 B-clinical_variable
bilirubin 45 54 3723 3732 I-clinical_variable
= 55 56 3733 3734 O
< 56 57 3734 3735 O
ULN 58 61 3736 3739 O
for 62 65 3740 3743 O
subjects 66 74 3744 3752 O
with 75 79 3753 3757 O
total 80 85 3758 3763 B-clinical_variable
bilirubin 86 95 3764 3773 I-clinical_variable
levels 96 102 3774 3780 I-clinical_variable
> 103 104 3781 3782 O
1.5 105 108 3783 3786 B-lower_bound
ULN 109 112 3787 3790 I-lower_bound
, 112 113 3790 3791 O
performed 114 123 3792 3801 O
within 124 130 3802 3808 O
28 131 133 3809 3811 B-upper_bound
days 134 138 3812 3816 I-upper_bound
of 139 141 3817 3819 O
treatment 142 151 3820 3829 B-treatment
initiation 152 162 3830 3840 O

activated 0 9 3841 3850 B-clinical_variable
partial 10 17 3851 3858 I-clinical_variable
thromboplastin 18 32 3859 3873 I-clinical_variable
time 33 37 3874 3878 I-clinical_variable
( 38 39 3879 3880 I-clinical_variable
aPTT 39 43 3880 3884 I-clinical_variable
) 43 44 3884 3885 I-clinical_variable
= 45 46 3886 3887 O
< 46 47 3887 3888 O
1.5 48 51 3889 3892 B-upper_bound
x 52 53 3893 3894 I-upper_bound
ULN 54 57 3895 3898 I-upper_bound
unless 58 64 3899 3905 O
subject 65 72 3906 3913 O
is 73 75 3914 3916 O
receiving 76 85 3917 3926 O
anticoagulant 86 99 3927 3940 B-treatment
therapy 100 107 3941 3948 I-treatment
as 108 110 3949 3951 O
long 111 115 3952 3956 O
as 116 118 3957 3959 O
PT 119 121 3960 3962 O
or 122 124 3963 3965 O
PTT 125 128 3966 3969 O
is 129 131 3970 3972 O
within 132 138 3973 3979 O
therapeutic 139 150 3980 3991 O
range 151 156 3992 3997 O
of 157 159 3998 4000 O
intended 160 168 4001 4009 O
use 169 172 4010 4013 O
of 173 175 4014 4016 O
anticoagulants 176 190 4017 4031 B-treatment
, 190 191 4031 4032 O
performed 192 201 4033 4042 O
within 202 208 4043 4049 O
28 209 211 4050 4052 B-upper_bound
days 212 216 4053 4057 I-upper_bound
of 217 219 4058 4060 O
treatment 220 229 4061 4070 B-treatment
initiation 230 240 4071 4081 O

agree 0 5 4082 4087 B-contraception_consent
to 6 8 4088 4090 I-contraception_consent
use 9 12 4091 4094 I-contraception_consent
two 13 16 4095 4098 I-contraception_consent
methods 17 24 4099 4106 I-contraception_consent
of 25 27 4107 4109 I-contraception_consent
contraception 28 41 4110 4123 I-contraception_consent
starting 42 50 4124 4132 O
with 51 55 4133 4137 O
the 56 59 4138 4141 O
first 60 65 4142 4147 O
dose 66 70 4148 4152 O
of 71 73 4153 4155 O
study 74 79 4156 4161 B-treatment
therapy 80 87 4162 4169 I-treatment
through 88 95 4170 4177 O
120 96 99 4178 4181 B-upper_bound
days 100 104 4182 4186 I-upper_bound
after 105 110 4187 4192 I-upper_bound
the 111 114 4193 4196 O
last 115 119 4197 4201 O
dose 120 124 4202 4206 O
of 125 127 4207 4209 O
study 128 133 4210 4215 O
therapy 134 141 4216 4223 O

be 0 2 4224 4226 O
willing 3 10 4227 4234 O
and 11 14 4235 4238 O
able 15 19 4239 4243 O
to 20 22 4244 4246 O
comply 23 29 4247 4253 O
with 30 34 4254 4258 O
the 35 38 4259 4262 O
requirements 39 51 4263 4275 O
of 52 54 4276 4278 O
the 55 58 4279 4282 O
REMS 59 63 4283 4287 B-treatment
program 64 71 4288 4295 I-treatment

currently 0 9 4296 4305 O
participating 10 23 4306 4319 O
and 24 27 4320 4323 O
receiving 28 37 4324 4333 O
study 38 43 4334 4339 B-treatment
therapy 44 51 4340 4347 I-treatment
or 52 54 4348 4350 O
has 55 58 4351 4354 O
participated 59 71 4355 4367 O
in 72 74 4368 4370 O
a 75 76 4371 4372 O
study 77 82 4373 4378 O
of 83 85 4379 4381 O
an 86 88 4382 4384 O
investigational 89 104 4385 4400 B-treatment
agent 105 110 4401 4406 I-treatment
and 111 114 4407 4410 O
received 115 123 4411 4419 O
study 124 129 4420 4425 B-treatment
drug 130 134 4426 4430 I-treatment
or 135 137 4431 4433 O
using 138 143 4434 4439 O
an 144 146 4440 4442 O
investigation 147 160 4443 4456 B-treatment
device 161 167 4457 4463 I-treatment
within 168 174 4464 4470 O
4 175 176 4471 4472 B-upper_bound
weeks 177 182 4473 4478 I-upper_bound
of 183 185 4479 4481 O
the 186 189 4482 4485 O
first 190 195 4486 4491 B-treatment
dose 196 200 4492 4496 I-treatment
of 201 203 4497 4499 I-treatment
treatment 204 213 4500 4509 I-treatment

enrolled 0 8 4510 4518 O
in 9 11 4519 4521 O
the 12 15 4522 4525 O
lenalidomide 16 28 4526 4538 B-treatment
cohort 29 35 4539 4545 O
must 36 40 4546 4550 O
adhere 41 47 4551 4557 O
to 48 50 4558 4560 O
the 51 54 4561 4564 O
scheduled 55 64 4565 4574 O
pregnancy 65 74 4575 4584 B-pregnancy
testing 75 82 4585 4592 O
as 83 85 4593 4595 O
required 86 94 4596 4604 O
in 95 97 4605 4607 O
the 98 101 4608 4611 O
Revlimid 102 110 4612 4620 O
Risk 111 115 4621 4625 O
Evaluation 116 126 4626 4636 O
and 127 130 4637 4640 O
Mitigation 131 141 4641 4651 O
Strategy 142 150 4652 4660 O
( 151 152 4661 4662 O
REMS 152 156 4662 4666 O
) 156 157 4666 4667 O
program 158 165 4668 4675 O

enrolled 0 8 4676 4684 O
in 9 11 4685 4687 O
the 12 15 4688 4691 O
lenalidomide 16 28 4692 4704 B-treatment
containing 29 39 4705 4715 O
cohort 40 46 4716 4722 O
( 47 48 4723 4724 O
cohort 48 54 4724 4730 O
2 55 56 4731 4732 O
) 56 57 4732 4733 O
must 58 62 4734 4738 O
be 63 65 4739 4741 O
registered 66 76 4742 4752 O
into 77 81 4753 4757 O
the 82 85 4758 4761 O
mandatory 86 95 4762 4771 O
Revlimid 96 104 4772 4780 O
REMS 105 109 4781 4785 O
program 110 117 4786 4793 O

female 0 6 4794 4800 B-gender
subjects 7 15 4801 4809 I-gender

female 0 6 4810 4816 B-gender
subjects 7 15 4817 4825 I-gender
of 16 18 4826 4828 O
childbearing 19 31 4829 4841 O
potential 32 41 4842 4851 O

have 0 4 4852 4856 O
a 5 6 4857 4858 O
negative 7 15 4859 4867 B-pregnancy
urine 16 21 4868 4873 I-pregnancy
or 22 24 4874 4876 I-pregnancy
serum 25 30 4877 4882 I-pregnancy
pregnancy 31 40 4883 4892 I-pregnancy
test 41 45 4893 4897 O
within 46 52 4898 4904 O
72 53 55 4905 4907 B-upper_bound
hours 56 61 4908 4913 I-upper_bound
prior 62 67 4914 4919 I-upper_bound
to 68 70 4920 4922 O
receiving 71 80 4923 4932 O
the 81 84 4933 4936 O
first 85 90 4937 4942 O
dose 91 95 4943 4947 O
of 96 98 4948 4950 O
study 99 104 4951 4956 O
medication 105 115 4957 4967 B-treatment

have 0 4 4968 4972 O
documented 5 15 4973 4983 O
rituximab 16 25 4984 4993 B-chronic_disease
- 25 26 4993 4994 I-chronic_disease
sensitive 26 35 4994 5003 I-chronic_disease
disease 36 43 5004 5011 I-chronic_disease
defined 44 51 5012 5019 O
as 52 54 5020 5022 O
a 55 56 5023 5024 O
documented 57 67 5025 5035 O
complete 68 76 5036 5044 O
or 77 79 5045 5047 O
partial 80 87 5048 5055 O
response 88 96 5056 5064 O
lasting 97 104 5065 5072 O
at 105 107 5073 5075 O
least 108 113 5076 5081 O
6 114 115 5082 5083 B-lower_bound
months 116 122 5084 5090 I-lower_bound
after 123 128 5091 5096 I-lower_bound
the 129 132 5097 5100 O
last 133 137 5101 5105 O
rituximab 138 147 5106 5115 O
containing 148 158 5116 5126 O

have 0 4 5127 5131 O
no 5 7 5132 5134 O
evidence 8 16 5135 5143 O
of 17 19 5144 5146 O
new 20 23 5147 5150 O
or 24 26 5151 5153 O
enlarging 27 36 5154 5163 O
brain 37 42 5164 5169 B-cancer
metastases 43 53 5170 5180 I-cancer

not 0 3 5181 5184 O
using 4 9 5185 5190 O
steroids 10 18 5191 5199 B-treatment
for 19 22 5200 5203 O
at 23 25 5204 5206 O
least 26 31 5207 5212 O
7 32 33 5213 5214 B-upper_bound
days 34 38 5215 5219 I-upper_bound
prior 39 44 5220 5225 I-upper_bound
to 45 47 5226 5228 O
trial 48 53 5229 5234 B-treatment
treatment 54 63 5235 5244 I-treatment

pregnant 0 8 5245 5253 B-pregnancy

receiving 0 9 5254 5263 O
systemic 10 18 5264 5272 B-treatment
steroid 19 26 5273 5280 I-treatment
therapy 27 34 5281 5288 I-treatment
or 35 37 5289 5291 O
any 38 41 5292 5295 O
other 42 47 5296 5301 O
form 48 52 5302 5306 O
of 53 55 5307 5309 O
immunosuppressive 56 73 5310 5327 B-treatment
therapy 74 81 5328 5335 I-treatment
within 82 88 5336 5342 O
7 89 90 5343 5344 B-upper_bound
days 91 95 5345 5349 I-upper_bound
prior 96 101 5350 5355 I-upper_bound
to 102 104 5356 5358 O
the 105 108 5359 5362 O
first 109 114 5363 5368 O
dose 115 119 5369 5373 O
of 120 122 5374 5376 O
trial 123 128 5377 5382 B-treatment
treatment 129 138 5383 5392 I-treatment

starting 0 8 5393 5401 O
with 9 13 5402 5406 O
the 14 17 5407 5410 O
pre 18 21 5411 5414 O
- 21 22 5414 5415 O
screening 22 31 5415 5424 O
or 32 34 5425 5427 O
screening 35 44 5428 5437 O
visit 45 50 5438 5443 O
through 51 58 5444 5451 O
120 59 62 5452 5455 B-upper_bound
days 63 67 5456 5460 I-upper_bound
after 68 73 5461 5466 I-upper_bound
the 74 77 5467 5470 O
last 78 82 5471 5475 O
dose 83 87 5476 5480 O
of 88 90 5481 5483 O
trial 91 96 5484 5489 B-treatment
treatment 97 106 5490 5499 I-treatment

subjects 0 8 5500 5508 O
that 9 13 5509 5513 O
require 14 21 5514 5521 O
intermittent 22 34 5522 5534 O
use 35 38 5535 5538 O
of 39 41 5539 5541 O
bronchodilators 42 57 5542 5557 B-treatment
, 57 58 5557 5558 O
local 59 64 5559 5564 B-treatment
steroid 65 72 5565 5572 I-treatment
injections 73 83 5573 5583 I-treatment
or 84 86 5584 5586 I-treatment
inhaled 87 94 5587 5594 I-treatment
or 95 97 5595 5597 O
topical 98 105 5598 5605 B-treatment
steroids 106 114 5606 5614 I-treatment

subjects 0 8 5615 5623 O
with 9 13 5624 5628 O
hypothyroidism 14 28 5629 5643 B-chronic_disease
stable 29 35 5644 5650 O
on 36 38 5651 5653 O
hormone 39 46 5654 5661 B-treatment
replacement 47 58 5662 5673 I-treatment
or 59 61 5674 5676 O
Sjogren 62 69 5677 5684 B-chronic_disease
's 69 71 5684 5686 I-chronic_disease
syndrome 72 80 5687 5695 I-chronic_disease

subjects 0 8 5696 5704 O
with 9 13 5705 5709 O
vitiligo 14 22 5710 5718 B-chronic_disease
or 23 25 5719 5721 O
resolved 26 34 5722 5730 O
childhood 35 44 5731 5740 B-chronic_disease
asthma 45 51 5741 5747 I-chronic_disease
/ 51 52 5747 5748 O
atopy 52 57 5748 5753 B-chronic_disease

who 0 3 5754 5757 O
have 4 8 5758 5762 O
not 9 12 5763 5766 O
been 13 17 5767 5771 O
surgically 18 28 5772 5782 O
sterilized 29 39 5783 5793 O
or 40 42 5794 5796 O
have 43 47 5797 5801 O
not 48 51 5802 5805 O
been 52 56 5806 5810 O
free 57 61 5811 5815 O
from 62 66 5816 5820 O
menses 67 73 5821 5827 O
for 74 77 5828 5831 O
> 78 79 5832 5833 O
1 80 81 5834 5835 B-lower_bound
year 82 86 5836 5840 I-lower_bound

willing 0 7 5841 5848 B-contraception_consent
to 8 10 5849 5851 I-contraception_consent
use 11 14 5852 5855 I-contraception_consent
2 15 16 5856 5857 I-contraception_consent
methods 17 24 5858 5865 I-contraception_consent
of 25 27 5866 5868 I-contraception_consent
birth 28 33 5869 5874 I-contraception_consent
control 34 41 5875 5882 I-contraception_consent
or 42 44 5883 5885 O
be 45 47 5886 5888 B-contraception_consent
surgically 48 58 5889 5899 I-contraception_consent
sterile 59 66 5900 5907 I-contraception_consent
, 66 67 5907 5908 O
or 68 70 5909 5911 O
abstain 71 78 5912 5919 B-contraception_consent
from 79 83 5920 5924 I-contraception_consent
heterosexual 84 96 5925 5937 I-contraception_consent
activity 97 105 5938 5946 I-contraception_consent
for 106 109 5947 5950 O
the 110 113 5951 5954 O
course 114 120 5955 5961 O
of 121 123 5962 5964 O
the 124 127 5965 5968 O
study 128 133 5969 5974 O
through 134 141 5975 5982 O
120 142 145 5983 5986 B-upper_bound
days 146 150 5987 5991 I-upper_bound
after 151 156 5992 5997 I-upper_bound
the 157 160 5998 6001 O
last 161 165 6002 6006 O
dose 166 170 6007 6011 O
of 171 173 6012 6014 O
study 174 179 6015 6020 B-treatment
medication 180 190 6021 6031 I-treatment

with 0 4 6032 6036 O
histologic 5 15 6037 6047 O
proof 16 21 6048 6053 O
of 22 24 6054 6056 O
follicular 25 35 6057 6067 B-cancer
lymphoma 36 44 6068 6076 I-cancer
grade 45 50 6077 6082 O
1 51 52 6083 6084 O
, 52 53 6084 6085 O
2 54 55 6086 6087 O
, 55 56 6087 6088 O
or 57 59 6089 6091 O
3a 60 62 6092 6094 O
relapsing 63 72 6095 6104 O
after 73 78 6105 6110 O
at 79 81 6111 6113 O
least 82 87 6114 6119 O
one 88 91 6120 6123 B-lower_bound
prior 92 97 6124 6129 B-treatment
systemic 98 106 6130 6138 I-treatment
therapy 107 114 6139 6146 I-treatment
that 115 119 6147 6151 O
included 120 128 6152 6160 O
rituximab 129 138 6161 6170 B-treatment
( 139 140 6171 6172 O
or 140 142 6172 6174 O
other 143 148 6175 6180 O
monoclonal 149 159 6181 6191 B-treatment
CD20 160 164 6192 6196 I-treatment
antibody 165 173 6197 6205 I-treatment
) 173 174 6205 6206 O

with 0 4 6207 6211 O
histologic 5 15 6212 6222 O
proof 16 21 6223 6228 O
of 22 24 6229 6231 O
follicular 25 35 6232 6242 B-cancer
lymphoma 36 44 6243 6251 I-cancer
grade 45 50 6252 6257 O
1 51 52 6258 6259 O
, 52 53 6259 6260 O
2 54 55 6261 6262 O
, 55 56 6262 6263 O
or 57 59 6264 6266 O
3a 60 62 6267 6269 O
relapsing 63 72 6270 6279 O
after 73 78 6280 6285 O
at 79 81 6286 6288 O
least 82 87 6289 6294 O
two 88 91 6295 6298 B-lower_bound
prior 92 97 6299 6304 B-treatment
systemic 98 106 6305 6313 I-treatment
therapies 107 116 6314 6323 I-treatment
, 116 117 6323 6324 O
which 118 123 6325 6330 O
must 124 128 6331 6335 O
include 129 136 6336 6343 O
CAR 137 140 6344 6347 B-treatment
T 141 142 6348 6349 I-treatment
cell 143 147 6350 6354 I-treatment
therapy 148 155 6355 6362 I-treatment
or 156 158 6363 6365 O
histologic 159 169 6366 6376 O
proof 170 175 6377 6382 O
of 176 178 6383 6385 O
DLBCL 179 184 6386 6391 B-cancer
relapsing 185 194 6392 6401 O
after 195 200 6402 6407 O
at 201 203 6408 6410 O
least 204 209 6411 6416 O
two 210 213 6417 6420 O
prior 214 219 6421 6426 O
systemic 220 228 6427 6435 O
therapies 229 238 6436 6445 O
, 238 239 6445 6446 O
which 240 245 6447 6452 O
must 246 250 6453 6457 O
include 251 258 6458 6465 O
CAR 259 262 6466 6469 O
T 263 264 6470 6471 O
cell 265 269 6472 6476 O
therapy 270 277 6477 6484 O

with 0 4 6485 6489 O
previously 5 15 6490 6500 O
treated 16 23 6501 6508 O
CNS 24 27 6509 6512 B-cancer
lymphoma 28 36 6513 6521 I-cancer
and/or 37 43 6522 6528 O
lymphomatous 44 56 6529 6541 B-cancer
meningitis 57 67 6542 6552 I-cancer
may 68 71 6553 6556 O
participate 72 83 6557 6568 O
provided 84 92 6569 6577 O
they 93 97 6578 6582 O
are 98 101 6583 6586 O
stable 102 108 6587 6593 O
( 109 110 6594 6595 O
without 110 117 6595 6602 O
evidence 118 126 6603 6611 O
of 127 129 6612 6614 O
progression 130 141 6615 6626 O
by 142 144 6627 6629 O
imaging 145 152 6630 6637 O
for 153 156 6638 6641 O
at 157 159 6642 6644 O
least 160 165 6645 6650 O
four 166 170 6651 6655 B-lower_bound
weeks 171 176 6656 6661 I-lower_bound
prior 177 182 6662 6667 I-lower_bound
to 183 185 6668 6670 O
the 186 189 6671 6674 O
first 190 195 6675 6680 O
dose 196 200 6681 6685 O
of 201 203 6686 6688 O
trial 204 209 6689 6694 B-treatment
treatment 210 219 6695 6704 I-treatment
and 220 223 6705 6708 O
any 224 227 6709 6712 O
neurologic 228 238 6713 6723 O
symptoms 239 247 6724 6732 O
have 248 252 6733 6737 O
returned 253 261 6738 6746 O
to 262 264 6747 6749 O
baseline 265 273 6750 6758 O
) 273 274 6758 6759 O

